CBD Oil In Seizure Treatment
Allison Gatlin, Investors News , 7/26/2019
Epidiolex, as it's known in the U.S., is the first and only drug from the cannabis plant to gain Food and Drug Administration approval. The seizure treatment is a CBD oil. CBD, or cannabidiol, stands as one of more than 100 compounds known as cannabinoids found in the plant.
A better known cannabinoid is THC, or tetrahydrocannabinol. THC brings the euphoric high associated with marijuana. GW Pharma's seizure treatment doesn't contain THC. The CBD oil aims to reduce the number of seizures experienced by Lennox-Gastaut and Dravet patients.
In the U.S., Epidiolex can be used as a stand-alone drug. But the European panel recommended approval of Epidyolex in conjunction with a seizure treatment known as clobazam. Clobazam is already available as a generic drug in Europe, SVB Leerink's Goodman said.
"We believe the label difference should not be an issue as clobazam has been generic and is commonly used in both Lennox-Gastaut and Dravet syndromes," he said. "So most physicians, we believe, would be adding Epidyolex to that drug anyway, just as they do in the U.S. today."
GW Pharma Stock Rises
In the U.S., the CBD oil seizure treatment runs for $1,235 per 100-milliliter bottle. That translates to about $32,500 per year. The biotech company is aiming to price Epidyolex at about 70% of that, Goodman said.
Goodman kept his outperform rating on GW Pharma stock. On today's stock market, GW Pharma stock rose 3.2%, to 166.31.